Amgen Inc. (NASDAQ:AMGN - Free Report) - Zacks Research cut their Q3 2025 earnings per share (EPS) estimates for Amgen in a research note issued to investors on Wednesday, December 4th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $5.21 per share for the quarter, down from their previous estimate of $5.22. The consensus estimate for Amgen's current full-year earnings is $19.51 per share. Zacks Research also issued estimates for Amgen's Q3 2026 earnings at $5.42 EPS.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the prior year, the firm earned $4.96 earnings per share. Amgen's revenue for the quarter was up 23.2% on a year-over-year basis.
Other equities research analysts also recently issued research reports about the company. Dbs Bank upgraded Amgen to a "strong-buy" rating in a report on Monday, September 16th. Royal Bank of Canada decreased their price target on Amgen from $360.00 to $330.00 and set an "outperform" rating for the company in a report on Wednesday, November 27th. Wolfe Research started coverage on Amgen in a report on Friday, November 15th. They set a "peer perform" rating for the company. Sanford C. Bernstein started coverage on Amgen in a research note on Thursday, October 17th. They issued an "outperform" rating and a $380.00 price objective for the company. Finally, Leerink Partners lowered their price objective on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Amgen has a consensus rating of "Hold" and an average target price of $323.05.
Read Our Latest Report on Amgen
Amgen Stock Down 0.6 %
Shares of NASDAQ:AMGN traded down $1.75 during trading on Monday, reaching $272.58. 3,970,337 shares of the stock were exchanged, compared to its average volume of 4,574,809. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen has a 1-year low of $257.80 and a 1-year high of $346.85. The stock has a fifty day moving average of $306.58 and a two-hundred day moving average of $315.86. The firm has a market cap of $146.52 billion, a price-to-earnings ratio of 34.90, a price-to-earnings-growth ratio of 3.02 and a beta of 0.55.
Amgen Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.30%. The ex-dividend date is Monday, November 18th. Amgen's dividend payout ratio is currently 115.24%.
Institutional Investors Weigh In On Amgen
Several hedge funds have recently made changes to their positions in the business. Capital Performance Advisors LLP purchased a new stake in Amgen in the 3rd quarter valued at about $25,000. Hershey Financial Advisers LLC acquired a new stake in Amgen during the second quarter valued at approximately $30,000. Legacy Investment Solutions LLC bought a new stake in Amgen during the third quarter valued at $29,000. nVerses Capital LLC bought a new position in Amgen in the second quarter worth about $31,000. Finally, Bbjs Financial Advisors LLC bought a new stake in Amgen in the second quarter valued at $33,000. Institutional investors and hedge funds own 76.50% of the company's stock.
About Amgen
(
Get Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Read More
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
